S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

NRX Nurexone Biologic Inc

0.57

0.00 (0.00%)

01 Oct 2024 - Closed

Delayed by 15 minutes

New Collaboration Could Revolutionize Treatment of Chronic Spinal Cord Injuries

In January 2023,

To read the full story on AllPennyStocks.com, click here.

Nurexone Biologic (TSXV:NRX)
Historical Stock Chart
From Sep 2024 to Oct 2024

Click Here for more Nurexone Biologic Charts.

Nurexone Biologic (TSXV:NRX)
Historical Stock Chart
From Oct 2023 to Oct 2024

Click Here for more Nurexone Biologic Charts.

Nurexone Biologic Inc News

NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
Friday 27 September 2024 (5 days ago) • GlobeNewswire Inc.

NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences
Friday 13 September 2024 (3 weeks ago) • GlobeNewswire Inc.

NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
Saturday 7 September 2024 (4 weeks ago) • GlobeNewswire Inc.

NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Wednesday 28 August 2024 (1 month ago) • GlobeNewswire Inc.

NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
Saturday 24 August 2024 (1 month ago) • GlobeNewswire Inc.

NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
Friday 16 August 2024 (2 months ago) • GlobeNewswire Inc.

NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
Saturday 10 August 2024 (2 months ago) • GlobeNewswire Inc.

NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
Friday 2 August 2024 (2 months ago) • GlobeNewswire Inc.

Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma
Thursday 18 July 2024 (2 months ago) • GlobeNewswire Inc.

Updates from NurExone: Growth Conference Presentation and Website Relaunch
Friday 5 July 2024 (3 months ago) • GlobeNewswire Inc.

NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
Saturday 29 June 2024 (3 months ago) • GlobeNewswire Inc.

On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
Saturday 22 June 2024 (3 months ago) • GlobeNewswire Inc.

More Nurexone Biologic Inc News Articles

Commonwealth Bank Of Aus...

Gold vs US Dollar

S&P ASX 300 Metals and M...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions